EP Patent

EP2950097A1 — Podoplanin as a biomarker of the activation of PI3K/mTOR signaling in human tumors

Assigned to Universitaetsspital Basel USB · Expires 2015-12-02 · 10y expired

What this patent protects

The invention relates to the use of podoplanin as a biomarker of the activation of PI3K/mTor signaling in human tumors.

USPTO Abstract

The invention relates to the use of podoplanin as a biomarker of the activation of PI3K/mTor signaling in human tumors.

Drugs covered by this patent

Patent Metadata

Patent number
EP2950097A1
Jurisdiction
EP
Classification
—
Expires
2015-12-02
Drug substance claim
No
Drug product claim
No
Assignee
Universitaetsspital Basel USB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.